Business · 30/10/2012Updated: 10/17/2026 · 1 min read
National Institutes of Health to Consider Exclusive Evaluation Option License for Medicenna Therapeutics' Ubiquitin-Based Fusion Proteins
Summary
The National Institutes of Health is seeking to grant an exclusive evaluation option license to Medicenna Therapeutics for the use of its ubiquitin-based fusion proteins, which may be used to develop human therapeutics for cancer and neurological diseases, following the expiration of a certain period.